The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
Benzinga's options scanner just detected over 16 options trades for Moderna (NASDAQ:MRNA) summing a total amount of $1,134,726. At the same time, our algo caught 10 for a total amount of 1,113,875.
Earnings season continues, and we're here to spotlight the companies expected to report their financial results on the next ...
Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $2.68 per share, versus earnings of 55 cents per share in the year-ago period. Moderna projects quarterly ...